DRVN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Driven Brands Holdings Inc (DRVN) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is facing significant negative catalysts, including material accounting errors, multiple class action lawsuits, and deteriorating financial performance. The technical analysis indicates bearish trends, and there are no strong proprietary trading signals to suggest a reversal. Analysts have downgraded the stock, and hedge funds are selling heavily. The risks far outweigh any potential upside in the current scenario.
The technical indicators suggest a bearish trend. The MACD is slightly positive but expanding, while the RSI is neutral at 30.373. Moving averages are bearish, with SMA_200 > SMA_20 > SMA_5. Key support and resistance levels indicate the stock is trading near its pivot point of 10.486, with support at 10.131 and resistance at 10.842. Overall, the technical outlook is weak.
The only slightly positive indicator is the increase in gross margin by 7.68% YoY in Q3 2025.
Material accounting errors in financial statements for FY23, FY24, and Q1-Q3 FY
Multiple class action lawsuits for securities fraud and financial misreporting.
Significant stock price decline of nearly 40%.
Hedge funds are heavily selling, with a 489.23% increase in selling activity last quarter.
Analysts have downgraded the stock and lowered price targets significantly.
Delay in Q4 financial results and SEC filing extension request.
The company's financial performance is deteriorating. In Q3 2025, revenue dropped by -9.46% YoY to $535.68M. Net income plummeted by -507.19% YoY to $60.86M, and EPS fell by -511.11% YoY to $0.37. While gross margin increased by 7.68% YoY to 43.87%, this is overshadowed by the significant declines in revenue, net income, and EPS.
Analysts have downgraded the stock to Neutral from Overweight, citing material accounting errors, sluggish fundamentals, and concerns over EBITDA adjustments. Price targets have been significantly reduced, with Piper Sandler lowering it to $12 (from $19) and Goldman Sachs reducing it to $16.50 (from $19).
